Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: How strongly should we encourage patients to adhere to the 'old' therapies?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 11, 2015, Pages 1171-

  Heidenreich, F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; RECOMBINANT BETA INTERFERON; TERIFLUNOMIDE;

DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; LONG TERM CARE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; FEMALE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

FEMALE; HUMANS; INTERFERON BETA-1A; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84955383136     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-310763     Document Type: Editorial

References (5)

1. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53.
2. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50.
3. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3-14.
4. Kappos L, Kuhle J, Multanen J, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry 2015;86:1202-7.
5. [No authors listed]. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504. Erratum in: Lancet 1999;353:678.